Raul Santos Shares The Results of ORION-16: On The Efficacy and Safety of Inclisiran
Raul Santos, Researcher at ARO Hospital Israelita Albert Einstein, shared on LinkedIn:
”I’m delighted to share the results of ORION-16, which demonstrate the efficacy and safety of Inclisiran, a siRNA inhibitor of PCSK9, in pediatric patients with heterozygous familial hypercholesterolemia (FH) who had elevated LDL-C despite statin therapy.
Overall, LDL-C was reduced by 28-34%, with excellent tolerability.
Results are consistent with those of monoclonal antibodies, a 34-45% reduction that we had demonstrated in recent years.
Apparently, pediatric patients present less intense responses, albeit variable from person to person, than adults, despite similar reductions in circulating PCSK9.
In my opinion, this may result in possible lower adherence to baseline medications that were not disclosed or due to a different biology. Indeed, children and adolescents are not miniature adults.
ORION-16 reinforces the efficacy and safety of PCSK9 inhibitors in pediatric heterozygous FH.
It opens the possibility of a different posology to reduce LDL-C in patients who have severe hypercholesterolemia and remain with very high LDL-C despite statin and or ezetimibe therapy.
I’d like to thank Prof. Albert Wiegman and Novartis for the possibility to participate in this study.”
Read the full article here.
Article: Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial
Authors: Albert Wiegman, Amy L. Peterson, Eric Bruckert, Joep C. Defesche, Anja Schweizer, Jean Bergeron, María J. Chueca, Jeanine E. Roeters van Lennep, Raul D. Santos, Karl Otfried Schwab, Anastasia Lesogor, Sijia Zhang, Robert A. Hegele
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 29, 2026, 14:02Emma Lefrancais on Alarmin IL33 and Platelet Biology
-
Jan 29, 2026, 13:44Sia A: One of My Favorite Conversations from ASH
-
Jan 29, 2026, 13:34Sarah Matuja on Tanzania Stroke Project
-
Jan 29, 2026, 13:28Nancy Di Salvo on Amplifying Rare Disease Voices Through Partnership
-
Jan 29, 2026, 05:22Aravind Palraj Draws a Comparison Between APS and Lupus Cerebritis
-
Jan 29, 2026, 05:09Edina Cenko on Expanding Cardiovascular Risk: From Ischaemia to Emerging Frontiers
-
Jan 29, 2026, 04:58Anna Randi Shares the Latest Episode of The VWF and Angiogenesis Story from Her Lab
-
Jan 29, 2026, 04:49Ruah Alyamany on Her Contribution to Establishing The Role of IgM in APS
-
Jan 29, 2026, 04:42Jecko Thachil on ‘Break Through’ Thrombosis Despite DOAC Use